ALS (AMYOTROPHIC LATERAL SCLEROSIS)
Clinical trials for ALS (AMYOTROPHIC LATERAL SCLEROSIS) explained in plain language.
Never miss a new study
Get alerted when new ALS (AMYOTROPHIC LATERAL SCLEROSIS) trials appear
Sign up with your email to follow new studies for ALS (AMYOTROPHIC LATERAL SCLEROSIS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental cell therapy tested in 3 ALS patients
Disease control CompletedThis early study tested whether infusing a patient's own regulatory T cells (immune-calming cells) along with interleukin-2 injections is safe for people with ALS. Only 3 participants were enrolled, and the main goal was to check for side effects. The approach aims to slow diseas…
Matched conditions: ALS (AMYOTROPHIC LATERAL SCLEROSIS)
Phase: PHASE1 • Sponsor: The Methodist Hospital Research Institute • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could an iron scavenger slow ALS?
Disease control CompletedThis study tested whether deferiprone, a drug that removes excess iron, could safely slow the progression of ALS. Researchers gave the drug to 23 adults with ALS for several months. The goal was to see if reducing iron buildup in the brain might protect nerve cells and delay wors…
Matched conditions: ALS (AMYOTROPHIC LATERAL SCLEROSIS)
Phase: PHASE2 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
ALS biomarker study aims to unlock disease clues
Knowledge-focused CompletedThis completed study looked at 60 people — 30 with ALS and 30 healthy volunteers — to measure immune system and nerve damage markers in their blood and spinal fluid. The goal was to better understand the role of a specific immune pathway (IFN-alpha) in ALS. By linking these marke…
Matched conditions: ALS (AMYOTROPHIC LATERAL SCLEROSIS)
Sponsor: Ulysses Neuroscience LTD • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC